Sprint Bioscience, a fragment based drug discovery company, is growing its CRO business and speeds up the development of their in-house cancer metabolism pipe line.
In alliance with the company expansion, we are happy to welcome three new colleagues; Anne-Marie Wenthzel, Director Business Development with a strong background in life science sales and marketing , Louise Egeblad, Senior Scientist with responsibility for assay development, and Ulrika Ericsson, joining us from OctaPharma to hold the position as Principal Scientist Protein Science.
